Lupin Launches Desoximetasone Topical Spray in US | CORPORATE ETHOS

Lupin Launches Desoximetasone Topical Spray in US

By: | July 27, 2018
lupin

Jul 27: Pharma major Lupin Ltd on Friday announced the launch of its Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

According to Lupin, the product is the generic equivalent of Taro Pharmaceuticals USA Inc.’s Topicort Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older, the company said.

Desoximetasone Topical Spray, 0.25% had annual sales of approximately $18.7 million in the US (IQVIA MAT May 2018).